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Central Nervous System (CNS) injury may lead to irreversible damage to cognitive and 
motor abilities when injured. This is due to the inability of axons to regenerate. This thesis 
focuses on two methods of promoting axonal regeneration: microtubule stabilization and 
upregulation of the intrinsic growth capacity of the neuron via the mechanistic target of 
rapamycin (mTOR) pathway. Both have shown promising results in potentially being a 
therapeutic treatment for CNS trauma. This research seeks to (1) test a combinatorial method of 
axonal regeneration utilizing both methods simultaneously and (2) compare microtubule 
stabilization and upregulation of the mTOR pathway as neuronal regeneration methods. Aim 1 
serves to test the combinatorial treatment of Taxol, a microtubule stabilizer, and cRheb 
transfection, which upregulates the mTOR pathway, on neuronal cell cultures. Cells were 
cultured in either a growth-promoting substrate or a mix of growth-promoting and growth-
inhibitory substrates. The results of this study revealed combinatorial treatment of 2DIV Taxol 
application with cRheb transfection as a promising treatment that yielded significantly greater 
axonal outgrowth than either treatment alone. Aim 2 serves to compare the two established 
methods of axonal regeneration in the scientific community. Based off of a meta-analysis, results 
of this aim indicate upregulation of mTOR is more effective at promoting axonal regeneration 
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CHAPTER ONE: INTRODUCTION 
 
Background 
The Central Nervous System (CNS) consists of the brain and the spinal cord [1]. It plays 
an integral part in coordinating the actions of the human body, accomplishing this through 
cellular communication in the form of electrical signals [2]. These electrical signals, called 
action potentials, are transmitted through neuronal axons to target cells, which may be another 
neuron continuing the signal or a muscle cell that has to be contracted for movement [2]. Axons, 
therefore, play a critical role in cellular communication and connections, allowing for the body to 
properly function. 
Axonal damage caused by CNS injury is detrimental to this cellular communication. The 
negative effects of disrupted cellular communication are compounded by the CNS neuron's 
inability to regenerate, resulting in permanent loss of axonal function in maintaining its cellular 
connection [3-5]. This leads to irreversible damage and a decreased quality of life with 
conditions such as paralysis. CNS injury to the brain may also irreversibly result in permanent 
alterations to cognitive function, such as the loss of the ability to process information, in addition 
to impairing an individual’s motor function [1]. 
The prevalence of individuals with spinal cord injury (SCI) within the United States is 
estimated to be 250,000 to 368,000, with the most common cause being vehicular accidents [6]. 
Of those suffering from spinal cord injury in 2015, 20.2% experience complete paraplegia and 
12.3% experience complete tetraplegia [6]. 47.2% experience incomplete tetraplegia while 
19.6% experience incomplete paraplegia [6]. Only 0.7% of those who are afflicted with SCI are 
able to recover completely neurologically [6]. The average lifetime costs attributed to spinal cord 
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injury is estimated to be $5,100,941 for a 25 year old individual suffering from tetraplegia due to 
spinal cord injury occurring at cervical level 1 (C1) through C4, which is a high injury to the 
cervical spine near the neck [6]. Lifetime costs for those of the same age with low tetraplegia 
(C5-C8) is estimated to be $3,727,066 while costs for those with paraplegia is $2,494,338 [6]. 
The low chances of complete recovery following SCI and the high care costs associated with SCI 
illustrates the need for effective therapeutic methods of promoting axonal regeneration within the 
CNS. 
Many causes contribute to the inability of neurons of the CNS to regenerate. These 
causes include the inhibitory environment formed by the glial scar at the site of CNS trauma, the 
immune response to CNS trauma known as neuroinflammation, and neuronal exposure to 
inhibitory myelin proteins [3-5, 7, 8]. Intrinsic neuronal responses to CNS injury, such as axonal 
dieback and diminishing intrinsic growth capacity, also hinder regeneration [9-12]. 
However, potential methods have been discovered to promote neuronal regeneration. 
This includes upregulation of the mechanistic target of rapamycin (mTOR) signaling pathway, 
where Phosphatase and tensin homolog (PTEN), Rheb, S6 kinase 1 (S6K1), Tuberous Sclerosis 
Complex (TSC), Protein kinase B (AKT), Suppressor of Cytokine Signaling 3 (SOCS3), Histone 
Deacetylase 5 (HDAC5), and Melanopsin are all among the proteins targeted to promote axonal 
regeneration [11-20]. Microtubule stabilization through the use of Taxol, epothilones, fidgetin 
knockdown, fibroblast growth factor 13 (FGF13) overexpression, and Metformin is another 
method to promote neuronal regeneration [21-26]. This study serves to compare the two 




One obstacle injured neurons must overcome in order to regenerate is the inhibitory 
environment that is created in the CNS within the injury site after trauma occurs. This inhibitory 
environment is termed the glial scar, which contains inhibitory chondroitin sulfate proteoglycans 
(CSPGs) [5, 27-29]. Neuroinflammation also contributes to the inhibitory environment, allowing 
for the infiltration of cells such as microglia, neutrophils, and macrophages [3]. The last aspect of 
the inhibitory environment hindering axonal regeneration are the components of myelin, 
including Nogo-A and myelin-associated glycoprotein (MAG) [4, 30-32]. 
 
Glial Scar 
The formation of a glial scar at the area where the injury disrupted the blood-brain barrier 
(BBB) contributes to the inhibitory environment that prevents neuronal regeneration [5]. The 
glial scar is formed when astrocytes, typically involved in neuronal environment regulation, 
become hypertrophic and reactive [27]. The reactive astrocytes produce a large amount of 
proteoglycans, specifically chondroitin sulfate proteoglycans (CSPGs), inhibitory to axonal 
growth [27]. This response by the reactive astrocytes is termed reactive gliosis [5]. 
Neurons were unable to regenerate past the border of CSPGs, indicating that the glial 
scar's boundaries align with the spatial spread of CSPGs [5, 28, 29]. CSPGs are distributed as a 
gradient within the CNS injury site, with the highest concentrations at the epicenter and lower 
concentrations at the outer edges [29, 33]. The main component of CSPGs that is responsible for 
its inhibitory effects on axonal regeneration is believed to be the sulphated glycosaminoglycan 
(GAG) side chain [34, 35]. This is evidenced by observed axonal regeneration after CNS injury 
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when the enzyme chondroitinase ABC (chABC) was used [14, 34-36]. ChABC specifically 
cleaves the GAG component of CSPGs [37].  
In a study conducted by Lang et al. (2015), it was also observed that Protein Tyrosine 
Phosphatase σ (PTPσ), a receptor for the CSPG side chains, may play a role in converting the 
axons into a dystrophic state and thus, preventing them from regenerating following trauma [38].  
PTPσ became concentrated in the areas of dystrophic growth cones following injury, as opposed 
to its even distribution prior to trauma when axons are still motile [38]. This high concentration 
of PTPσ in SCI lesions may serve to hyper-stabilize axons within the CSPGs, preventing 
regeneration. Lang et al. (2015) then utilized an Intracellular Sigma Peptide (ISPs) to modulate 
PTPσ and this method yielded results comparable to the use of chABC [38]. Therefore, it is 
indicated that PTPσ is another component of the glial scar that contributes to the inability for 
axons to regenerate. 
 
Neuroinflammation 
When an injury occurs in the CNS, the body immediately begins steps to prevent further 
damage from the injury. These steps include inflammation of the injury site, which is a 
mechanism that occurs throughout the body to contain an injury. In the case of CNS injury, 
neuroinflammation occurs [3]. Neuroinflammation causes an increase in the permeability of the 
BBB, allowing for microglia, macrophages, and leukocytes such as neutrophils to enter the site 
of CNS injury [3]. 
Activated macrophages, microglia, and neutrophils secrete pro-inflammatory molecules 
that include Matrix Metalloproteinase-9 (MMP-9) and Interleukin-6 (IL-6) to induce the 
inflammatory response [3]. Secretions of both allow for increased BBB permeability to 
leukocytes and macrophages, linking the molecules to axonal degeneration [39, 40]. In addition, 
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infiltrating microglia, neutrophils, and macrophages produce both nitric oxide and superoxide 
anion [3, 41, 42]. These two combine and produce peroxynitrite, a toxic substance causing 
neuronal toxicity and oxidative stress, hindering axonal recovery [3, 41, 42]. Thus, 
neuroinflammation also contributes to the inhibitory environment that prevents axons from 
regenerating, despite its beneficial purpose in containing the injury.  
 
Myelin 
Myelin is another component within the CNS that becomes inhibitory to axonal 
outgrowth after CNS trauma [4]. Oligodendrocytes mainly function to produce the myelin sheath 
in the CNS. The myelin sheath is responsible for insulating the axon, allowing for action 
potentials to travel quickly and efficiently down axons to its target. Schwab et al. (1988) showed 
when neuroblastoma cells were stimulated to regenerate, no outgrowth occurred in areas with 
dense populations of mature oligodendrocytes or when myelin from an adult rat spinal cord was 
used as a substrate [4]. In contrast, Savio et al. (1990) observed substrate without myelin resulted 
in longer axonal outgrowth [8]. 
The membrane protein Nogo is implicated as the component of myelin and 
oligodendrocytes that inhibits axonal regeneration [30]. Specifically, the isoform Nogo-A is 
involved in axonal regeneration inhibition due to the high levels of expression of Nogo-A on 
oligodendrocytes and in myelin membranes [43]. The Nogo-66 region of Nogo-A binding to 
membrane protein NgR1 leads to the activation of rho A and rho-associated protein kinase 
(ROCK) [31, 44, 45]. Both downstream effectors cause the collapse of the growth cone and 
subsequent arrest of neuronal growth, preventing axonal regeneration [31, 44, 45]. Another 
component of myelin that is found to contribute to its inhibitory effect on axonal regeneration is 
Myelin-associated glycoprotein (MAG), which is found within the myelin membrane and is 
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involved in axon stabilization [46, 47]. When myelin is damaged during CNS injury, axons are 
exposed to MAG and retract when they come in direct contact with MAG, preventing axonal 
regeneration [7, 32].  
 
Neuronal Response to CNS Injury 
The second obstacle damaged axons have to overcome is the intrinsic neuronal responses 
to CNS injury. Following injury to the CNS, neurons will exhibit axonal dieback, hindering 
axons from regenerating out of the injury [10, 29, 36]. The intrinsic growth capacity of the 
neuron also decreases following CNS injury, further preventing neuronal regeneration [11, 12]. 
 
Axonal Dieback 
The inhibitory factors previously stated all contribute to a phenomenon in axons that 
restricts its ability to regenerate: axonal dieback. After CNS injury, neuronal axons develop 
dystrophic endings, which were first described by Ramón y Cajal [10]. Axonal dieback is the 
retraction of the dystrophic endbulbs of axons from the injury site, resulting in the axon’s 
inability to regenerate and grow past the glial scar [10, 29, 36]. Axonal dieback results from 
microglia, acute axonal degeneration, the presence of CSPGs, and activated macrophages that 
secrete MMP-9 in response to inflammation. 
There are two phases of axonal dieback following CNS injury. The first phase occurs 
immediately following the CNS injury and is macrophage-independent [9, 48]. Microglia, the 
first cells to respond to CNS injury, and acute axonal degeneration, a process intrinsic to 
neurons, are responsible for retraction at this phase [9, 48]. The second phase occurs after 
macrophage infiltration of the CNS injury site approximately three days after CNS injury [9]. 
 7 
Direct contact between macrophages and axons mediated by MMP-9 induced axonal dieback 
when excess CSPGs are present in the extracellular matrix [9, 36, 40]. 
 
Diminished Intrinsic Growth Capacity: mTOR Signaling Pathway 
A signaling pathway that governs the intrinsic growth capacity of CNS neurons is the 
mechanistic target of rapamycin (mTOR) signaling pathway, which regulates cellular 
metabolism, cellular growth, and cellular proliferation [49]. The protein central to this pathway, 
mTOR, is a serine-threonine kinase made up of two complexes: mTOR Complex 1 (mTORC1) 
and mTOR Complex 2 (mTORC2) [49]. 
mTORC1 positively regulates cell growth and proliferation by promoting anabolic 
processes, such as biosynthesis, and limiting catabolic processes [49]. One effector protein of 
mTORC1 is S6 Kinase 1, which produces new ribosomes and induces cap-dependent translation 
initiation [50, 51]. mTORC1 is negatively regulated by the protein Tuberous Sclerosis Complex 
(TSC). TSC keeps Rheb, the direct activating protein of mTORC1, bound to guanosine 
diphosphate (GDP) and inactive [49, 52]. Only when Rheb is attached to guanosine triphosphate 
(GTP) will it become active and interact with mTORC1 to stimulate mTORC1's activity [52]. 
mTORC2 promotes cellular growth and proliferation through phosphorylation of Protein Kinase 
B (AKT), a positive regulator of cellular growth as it inhibits TSC [49]. mTORC2 also regulates 
the organization of the cytoskeleton through actin polymerization [53]. 
The mTOR signaling pathway is downregulated in both an age-dependent and injury- 
dependent manner [11, 12]. mTOR pathway activity was measured by the presence of 
phosphorylated S6 (p-S6) ribosomal protein, a downstream effector of mTOR [11, 12]. 
Embryonic neurons are observed to have higher mTOR activity than neurons within adults as 
they contained a stronger p-S6 signal [11, 12]. This difference in mTOR activity indicates that 
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mTOR activity decreases as neurons mature [11, 12]. Injury to the axon also results in a rapid 




Figure 1. The mTOR signaling pathway. The mTOR signaling pathway promotes cellular growth and 
proliferation. The mTOR signaling pathway is downregulated as neurons mature or is drastically downregulated 
following neuronal injury. The central protein in the mTOR pathway is mTOR, which is formed by two complexes: 
mTORC1 and mTORC2.  
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Promotion of Neuronal Regeneration: Upregulation of mTOR Signaling Pathway 
Efforts have been made within the scientific community to discover potential methods to 
promote neuronal regeneration despite the obstacles that arise following CNS injury. One 
method is through the upregulation of the mTOR signaling pathway, a pathway involved in 
cellular growth [49]. Targets of the pathway include PTEN, Rheb, S6K1, TSC, and AKT [11-14, 
16]. Targets outside the mTOR pathway that also upregulate mTOR consist of SOCS3, HDAC5, 
and melanopsin [15, 17-19]. 
 
Inhibition of PTEN 
Phosphatase and tensin homolog (PTEN) protein is one target used to promote neuronal 
regeneration. PTEN is a tumor suppressor that downregulates the mTOR signaling pathway [51]. 
PTEN phosphorylates phosphatidylinositol-3,4,5-triphosphate to inhibit phosphatidylinositol-3-
kinase (PI3K), a kinase needed to activate mTOR since PI3K activates AKT [50, 51]. Studies 
involving the deletion of the PTEN gene resulted in axonal sprouting into CNS lesions and the 
re-formation of synapses after CNS injury, with increased p-S6 signals confirming the 
upregulation of mTOR [11, 12]. PTEN suppression using short-hairpin RNA also was shown to 
enhance the intrinsic growth capacity of neurons as corticospinal tract (CST) axons of mice with 
PTEN suppressed grew across CNS lesions and re-formed synapses [54]. Drugs, such as 
bisperoxovandaium (bpV) compounds, are also used in PTEN inhibition [55]. bpV application 
promoted neuronal regeneration following CNS injury [56]. 
 
Activation of Rheb 
Rheb is another target within the mTOR signaling pathway for neuronal regeneration as it 
is a GTPase that directly activates mTORC1 [52]. One way to increase Rheb activation of mTOR 
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is by utilizing constitutively active Rheb (cRheb) to promote axonal regeneration. The cRheb 
protein contains a point mutation that results in a mutant Rheb protein always bound to GTP and 
that is therefore always activated [57]. cRheb expression in adult rat neurons resulted in observed 
axonal outgrowth into a peripheral nerve graft within a spinal cord injury (SCI), showing that 
cRheb promoted axonal regeneration [14]. 
 
Activation and Inhibition of S6K1 
The protein kinase p70 ribosomal protein S6 kinase 1 (S6K1) is an effector protein of 
mTOR that phosphorylates target proteins that include elF4B and S6. Phosphorylation of elF4B 
by S6K1 initiates protein translation, contributing to cellular growth and proliferation [58]. A 
study utilizing a constitutively active S6K1 mutant (S6K1-CA) showed that continuous 
activation of S6K1 resulted in significantly greater axonal regeneration in mice following optic 
nerve crush than wild type mice and mice with the S6K1 dominant negative (S6K1-DN) mutant 
that downregulates S6K1 [20]. This supports the use of upregulation of S6K1 as a possible 
method of axonal regeneration. 
However, S6K1 also acts as a negative feedback regulator of the mTOR pathway by 
reducing PI3K signaling [59]. This negative feedback mechanism is crucial in preventing 
excessive cellular growth that characterizes cancer [60]. Therefore, inhibition of S6K1 was also 
studied as a potential mechanism of axonal regeneration as it would induce PI3K signaling. The 
study showed that both inhibition of S6K1 and knockdown of its target protein, S6, promoted 
CST axonal regeneration in mice after transection [13]. Therefore, both activation and inhibition 
of S6K1 allow for promotion of axonal regeneration following CNS injury. 
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Inhibition of TSC 
Tuberous Sclerosis Complex (TSC) is a negative regulator of mTOR as it prevents the 
activation of Rheb by maintaining Rheb’s contact with GDP [49]. It is a heterodimer comprised 
of two complexes: tuberous sclerosis complex 1 (TSC1) and tuberous sclerosis complex 2 
(TSC2) [49]. Due to its regulatory role in mTOR signaling, it is a potential target to promote 
neuronal regeneration. Knockdown of TSC1 resulted in strong p-S6 signals within RGCs of mice 
after optic nerve injury, indicating upregulation of mTOR as p-S6 is a downstream effector of 
mTOR [11, 12]. 
 
Activation of AKT 
Protein kinase B (AKT) inhibits TSC, which is a negative regulator to mTORC1 [49]. 
Therefore, AKT positively regulates the mTOR pathway when activated and is a target for 
upregulating the mTOR pathway. A study utilizing constitutively active AKT showed that 
upregulation of AKT activity promotes axonal regeneration in mice after optic nerve crush [16]. 
Specifically, of the three isoforms of AKT in RGCs, AKT3 was found to significantly promote 
greater axonal regeneration than the other two AKT isoforms of AKT1 and AKT2 [16].  
 
Inhibition of SOCS3 
While suppressor of cytokine signaling 3 (SOCS3) is a part of the Janus kinase/signal 
transducers and activators of transcription (JAK/STAT) signaling pathway as opposed to the 
mTOR pathway, it also functions to suppress the reactivation of the mTOR pathway following 
CNS injury through suppression of glycoprotein 130 (gp130), a receptor subunit that activates 
mTORC1 [61, 62]. Therefore, SOCS3 inhibition is used to allow for reactivation of the mTOR 
pathway after CNS injury, which was observed by Smith et al. (2009) when mTOR activity was 
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recovered following optic nerve crush in mice with the SOCS3 gene was deleted while mTOR 
activity remained diminished in controls [18]. Co-deletion of both SOCS3 and PTEN was also 
shown to further enhance axonal regeneration following CNS injury than deletion of either 
protein alone [19].  
 
Alteration of HDAC5 Phosphorylation 
Histone Deacetylase 5 (HDAC5) indirectly activates the mTOR pathway as its inhibition 
or silencing has the effect of also suppressing mTORC1 [63]. A study conducted by Pita-Thomas 
et al. (2019) further discovered that transduction of an HDAC5AA mutant in mice, in which 
serine 259 and 488 were replaced with alanine to prevent phosphorylation those two sites, 
upregulated the mTOR pathway [17]. HDAC5AA also promoted greater regeneration of the optic 
nerve following optic nerve crush compared to the wild type protein [17].  
 
Overexpression of Melanopsin 
 The subset of retinal ganglion cells (RGCs) that is able to survive following optic nerve 
axotomy are Type 1 melanopsin-expressing, intrinsically photosensitive retinal ganglionic cells 
(M1 ipRGCs) [64]. This subset of RGCs expresses higher levels of melanopsin, a photopigment 
that allows for ipRGCs to respond to light, than other subset RGCs [64, 65]. Their ability to 
survive is linked to maintenance of mTOR activity following CNS injury, despite mTOR 
typically being downregulated following injury [15]. Melanopsin was discovered to be what 
allowed for M1 ipRGCs, along with M2 ipRGCs and M3 ipRGCs that also express high levels of 
melanopsin, to maintain their mTOR activity following axotomy as it activates mTORC1 
through Gq/11 signaling initiated by light stimulation [15]. Furthermore, overexpression of 
melanopsin resulted in axonal regeneration in mice following optic nerve crush [15]. 
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Promotion of Neuronal Regeneration: Microtubule Stabilization 
A second method of neuronal regeneration that shows promising results is microtubule 
stabilization. Microtubule stabilization allows for axons to elongate instead of depolymerize [22, 
24, 66]. Mechanisms of microtubule stabilization include chemotherapeutic drugs, fidgetin 
knockdown, fibroblast growth factor 13 (FGF13) overexpression, and Metformin [21-26]. 
 
Chemotherapeutic Drugs 
Microtubule stabilization via the use of chemotherapeutic drugs is a viable mechanism of 
axonal regeneration as it both inhibits the depolymerization of axonal microtubules and 
decreases glial scar formation, allowing for axonal elongation and regeneration. The two 
microtubule-stabilizing reagents used in studies of axonal regeneration are paclitaxel, also known 
as Taxol, and epothilones [22-24]. Taxol is a chemotherapeutic drug that interferes with cell 
growth and division, preventing the overgrowth of cells that characterizes cancer [24]. 
Epothilones are also chemotherapeutic medications that, in contrast to Taxol, are able to cross 
the BBB [22, 23]. The two classes of epothilones that have been used in axonal regeneration 
studies are epothilone B (epoB) and epothilone D (epoD) [22, 23]. 
Inhibition of the depolymerization of axonal microtubules prevents axonal dieback after 
CNS injury [22, 23, 67]. Tubulin, the main component of microtubules, is a heterodimer 
consisting of an α and β subunit [68]. During depolymerization, tubulin adopts a curved 
conformation. Taxol and epothilones bind to the β subunit of tubulin, forcing tubulin to have a 
straight conformation that opposes depolymerization [68, 69]. However, only low concentrations 
of Taxol and epoB were shown to enhance axonal regeneration as it restricts microtubule 
depolymerization while maintaining the dynamic nature of microtubules within the axons at the 
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plus ends, allowing for the axons to continue to grow [22, 24, 66]. High concentrations of 
microtubule-stabilizing reagents would inhibit both the dynamicity and depolymerization of 
axonal microtubules. 
Glial scar formation is decreased as the intracellular trafficking of extracellular matrix 
(ECM), such as CSPGs, is disrupted. Reactive astrocytes secrete an excess amount of CSPGs 
during CNS injury [27]. The intracellular trafficking of ECMs and its secretion into the 
extracellular space depends on microtubules, which comprise the tracks of transport within the 
cell [70]. After application of Taxol and epoB to the site of CNS injury, disruption of the 
transportation of ECMs was evident with localization of CSPGs intracellularly and decreased 
CSPGs in the site of CNS injury [22, 71]. 
 
Fidgetin Knockdown  
Fidgetin knockdown is an alternative method of microtubule stabilization shown to 
increase neuronal regeneration that does not rely on chemotherapeutic drugs. Fidgetin is a 
protein that cleaves unstable microtubules [72]. It is believed that fidgetin cleaves mainly 
unstable microtubules due to its preferences for tubulin lacking acetylation, which is a 
characteristic of unstable microtubules [72]. Knockdown of fidgetin prevents microtubule 
cleavage and has been shown to promote axonal regeneration in vitro in adult rat dorsal root 
ganglion neurons and in vivo in rats that underwent a dorsal root crush [21]. 
 
Overexpression of FGF13 
Fibroblast growth factor 13 (FGF13) is a nonsecretory protein within the fibroblast 
growth factors (FGFs) family [73]. FGFs play a regulatory role during the development of the 
nervous system. FGF13 specifically is seen to play a role in the development of cortical neurons 
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within the cerebrum, facilitating neuronal development through stabilizing microtubules [73]. A 
study conducted by Li et al. (2018) overexpressed FGF13 within the spinal cord of rats and 
observed enhanced axonal regeneration following SCI, demonstrating that FGF13 may be a 
viable method of promoting axonal regeneration [25]. 
 
Metformin 
  Metformin is a drug normally prescribed to individuals with type 2 diabetes as its main 
function is to lower glucose levels [74]. However, a study conducted by Wang et al. (2020) 
found that Metformin also promoted axonal regeneration following SCI in rats through activation 
of the PI3K/Akt signaling pathway [26]. This pathway allowed for the stabilization of 
microtubules as Wang et al. (2020) observed a significant increase in the ratio of Ace-tubulin, a 
stable microtubule, to Tyr-tubulin, an unstable microtubule that is dynamic [26]. Microtubule 
stabilization through Metformin administration is another promising method of promoting axonal 




Figure 2. An overview of microtubule stabilization and upregulation of the mTOR pathway as two methods 
of promoting neuronal regeneration. Adapted from the University of California – San Diego [75]. The left 
illustrates microtubule stabilization, which includes application of Taxol, epothilones, and Metformin as well as 
upregulation of FGF13 and downregulation of fidgetin. The right illustrates upregulation of the mTOR pathway. 
Upregulation of mTOR is accomplished through downregulation of PTEN, TSC, SOCS3, and S6K1 as well as 









































Aim 1: Combinatorial application of Paclitaxel (Taxol) and upregulation of mTOR via 
constitutively active Rheb (cRheb) in vitro 
Under the leadership of Dr. Alicia Hawthorne, I, along with Lauren Martin, Luis Benitez, 
and Neil Aleger, designed and conducted a study that combined microtubule stabilization and 
upregulation of mTOR to potentially promote neuronal regeneration on both growth-inhibitory 
and growth-promoting substrates in vitro. We predicted the combinatorial treatment of Taxol and 
cRheb will further enhance regeneration than either treatment alone. Results of this study 
indicated that the combinatorial treatment involving two-day 3 nM Taxol application and cRheb 
transfection yielded significantly longer axonal lengths than either treatment alone in the 
stimulatory substrate. This finding suggests that a combination of both approaches is a viable 
method of axonal regeneration. 
 
Aim 2: Meta-Analysis Comparison of Two Neuronal Regeneration Approaches: 
Upregulation of mTOR versus Microtubule Stabilization 
A meta-analysis comparison was then performed independently to compare two 
approaches used in the scientific community to promote neuronal regeneration: upregulation of 
the mTOR pathway and microtubule stabilization. It is predicted that microtubule stabilization 
would be more effective at enhancing neuronal regeneration based on our observations in vitro. 
A literature search yielded a collection of studies using either method. Data was extracted and 
statistically analyzed. Results of the meta-analysis proved our hypothesis incorrect and indicated 
that upregulation of the mTOR pathway was more effective at promoting axonal regeneration 
than microtubule stabilization. 
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CHAPTER TWO: COMBINATORIAL EFFECT OF CONSTITUTIVELY 
ACTIVE RHEB AND TAXOL ON AXONAL REGENERATION IN VITRO  
 
Introduction 
Upregulation of the mTOR pathway within neurons is one method of promotion of 
neuronal regeneration used in the scientific community. The mTOR pathway regulates the 
intrinsic growth capacity of neurons as it controls cellular growth and proliferation [49]. 
Upregulation of the mTOR pathway increases the neuron’s intrinsic growth capacity, which is 
reduced as a factor of time and injury [11, 12]. Rheb is a protein within the mTOR pathway and 
is a viable target to upregulate the pathway. As a GTPase, Rheb activates the protein complex 
mTORC1, which promotes anabolic processes required for cellular growth [49, 52]. A study 
conducted by Wu et. al utilized constitutively active Rheb (cRheb), a mutant Rheb that is always 
activated due to it always being bound to GTP, to promote axonal regeneration in adult rat 
neurons following spinal cord injury (SCI) [14, 57]. Axonal outgrowth was observed in the 
peripheral nerve graft within the injury, showing that cRheb transfection promoted axonal 
regeneration [14]. 
The use of microtubule stabilization via chemotherapeutic drugs is another method to 
promote neuronal regeneration. The microtubule stabilization properties of chemotherapeutic 
drugs prevent the axons from depolymerizing when injured, allowing for axonal elongation 
instead [22, 23, 67]. It also affects the microtubules used by the cell for intracellular trafficking 
of materials. This prevents glial scar formation as the secretion of ECMs, including CSPGs, is 
reduced [22, 70, 71]. Taxol, a chemotherapeutic drug, has been observed in a study conducted by 
Sengottuvel et. al to enhance the regeneration of mature retinal ganglion cells’ axons after optic 
nerve injury [24].  
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To our knowledge, no study has been published that combined both methods of neuronal 
regeneration in order to further enhance neuronal regeneration. We designed and conducted a 
study that combined microtubule stabilization and upregulation of mTOR to potentially promote 
neuronal regeneration in both inhibitory and stimulatory substrates. The application of Taxol was 
used as the microtubule stabilizing reagent, while transfection of a plasmid expressing cRheb 
was used for the upregulation of mTOR. We predicted that the combinatorial treatments of Taxol 
and cRheb transfection would yield significantly longer axons than either treatment alone, as the 
approaches target different intracellular pathways. 
 
Materials and Methods 
Cell Culture 
 Two neuronal cell lines were used: mouse/rat hybrid sensory neuronal cell line F11 and 
mouse neuroblastoma Neuro2a (N2a) [76, 77]. Cells were cultured and split in media consisting 
of Dulbecco’s Modified Eagle Medium (DMEM), 10% fetal bovine serum (FBS), and 1% 
Pen/Strep. When about 80% confluent, cells were split using trypsin.  The cells were incubated at 




The coverslips were sterilized through a 15-minute wash in 70% EtOH and three 
consecutive dH2O washes, with the coverslips stored in the third wash. The coverslips were then 
transferred to four 24-well plates. The coverslips were then treated with 400 μL of 1 μL/mL 
poly-L-lysine (PLL) per coverslip overnight at room temperature or two hours at 37°C. The PLL 
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was then removed and the coverslips were treated with three consecutive washes of dH2O, with 
the third wash left in.   
Laminin and Aggrecan 
 The stimulatory and inhibitory conditions within the CNS were simulated utilizing 
laminin and aggrecan substrates respectively. Laminin is a glycoprotein used for neuronal 
attachment, growth, and migration [78]. Aggrecan is a type of CSPG secreted by astrocytes after 
CNS injury, contributing to the formation of the glial scar which inhibits neuronal regeneration 
[79]. Aggrecan is a more heavily glycosylated CSPG compared to others CSPGs, making it more 
inhibitory to axonal regeneration than other CSPGs [79].  
  For the stimulatory experimental conditions, a 1 ug/mL laminin solution was created 
through dilution of stock laminin with HBSS. In the inhibitory experimental conditions, a 
solution consisting of laminin (1 μg/mL) and aggrecan (50 μg/mL) was created by diluting the 
stock solutions with HBSS. The dH2O from the third wash was aspirated from the wells. 400 μL 
of the 1 μg/mL laminin solution or the laminin (1 μg/mL) with aggrecan (50 μg/mL) solution 
was added to the appropriate wells, depending on the experimental condition the well was 
assigned to. The wells were incubated for two hours at 37°C. 
 The solutions were then aspirated from the wells. 400 μL of Neurobasal A media 
consisting of 48 mL Neurobasal A, 2% B27, 1% Pen/Strep, and 1% Glutamax was added to each 
well. Approximately 85,000 cells were then added to the wells containing Neurobasal A media. 
The plates were incubated overnight at 37°C.  
Transfection of cRheb 
The plasmid (pHAGE-CMV-Rheb(S16H)-IRES-eGFP-W) used for transfection contains 
the gene for cRheb, the gene for ampR, a gene for ampicillin resistance, and the gene coding for 
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the tag, Enhanced Green Fluorescent Protein (EGFP). The plasmid was selected from colonies 
grown on nutrient agar plates containing ampicillin and purified using the QIAGEN Plasmid 
Maxi Kit.  
A master mix was made that allowed for the following quantities to be added to each well 
within the experimental conditions requiring cRheb transfection: 25 μL of OPTI-MEM, 1.5 μL 
XHP, and 1 μg/μL of plasmid. The master mix was added evenly to each well after the 
Neurobasal A media was change. 0.2% Forskolin was also added to each well to promote 
neuronal differentiation and is added after each subsequent media change. Media was changed 
24 hours after transfection. For conditions that served to control for cRheb transfection, the same 
master mix was used with 1 μg/μL of plasmid replaced with the same quantity of sterile dH2O. 
Taxol Application 
Two different experimental conditions were simulated for Taxol application. The first 
condition consisted of Taxol applied to cells at the same time as transfection was carried out on 
the cells. In the second condition, Taxol was applied to cells 24 hours after transfection; the cells 
in this condition had one less day of exposure to Taxol than the first condition. 
A solution of 3 nM Taxol in Neurobasal A media was created. 3 nM Taxol was then 
added to the wells either the day of transfection or the following day, depending on the 
experimental condition. For conditions that controlled for Taxol application, media was made 





Figure 3. Experimental and control conditions in Aim 1. N2a and F11 cell lines were plated in Neurobasal-A 
Media on 1 μg/mL Laminin substrate or a 1 μg/mL Laminin and 50 μg/mL Aggrecan substrate. The following 
treatments were then applied the cell lines: 2 days in vitro (2-DIV) application of 3 nM Taxol, 3 days in vitro (3-
DIV) application of 3 nM Taxol, pcRheb-eGFP transfection, combinatorial treatment of pcRheb-eGFP transfection 
and 3-DIV 3 nM Taxol application, and combinatorial treatment of pcRheb-eGFP transfection and 2-DIV 3 nM 
Taxol application. Control groups included a DMSO control, a transfection control, and a combinatorial control 




 After 3 days in vitro, the cells were fixed with 4% cold paraformaldehyde for 15 minutes. 
The fixed cells were then washed with 1X phosphate buffered saline (PBS) three consecutive 
times. The cells were then blocked with 0.1% Triton-X 100, 0.1% Bovine Serum Albumin, 5% 
Normal Goat Serum in PBS for two hours at room temperature.  
The coverslips were then washed with PBS three consecutive times and transferred to 
humidifying chambers for staining. The coverslips were incubated with the primary antibodies 
(Mouse IgG α β-tubulin III; Rabbit α GFP; 1:250) overnight at 4°C. Then, after three consecutive 
1X PBS washes, the cells were incubated with the secondary antibodies (Goat α Rabbit IgG 
Alexa 488; Goat α Mouse IgG Alexa 568; 1:200) for two hours at room temperature. DAPI 
Cells plated in 
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(1:15,000) was applied to the cells for 10 minutes. Following the application of DAPI, the 
coverslips were washed with PBS three final times. 
 
Visualization 
 The coverslips were mounted on slides using Citifluor in a 1:1 dilution with PBS and 
sealed with nail polish. The mounted coverslips were stored at -20°C when they were not being 
visualized under the microscope. A Leica DMI3000 B inverted microscope and the Image-Pro 
Insight program was used to visualize the slides.  
 
Quantification 
 ImageJ, an image processing program developed by the National Institutes of Health 
(NIH), was used to quantify the cells. Specifically, Fiji, a program based off of ImageJ with all 
of the plugins, was used. The plugin NeuronJ allowed for the tracing and quantification of 
neurons. Visualizations of the cells on the coverslip were converted to 8-bit images using Fiji 
and then quantified with NeuronJ. The lengths of all distinguishable axons were traced and 
measured with a scale adjusted to 121.333 pixels/μm. Data were analyzed using SPSS software. 
 
Results 
N2a Cell Line: Growth Promoting Substrate 
 Within the experimental conditions that consisted of the N2a cell line exposed to only 
laminin, the combinatorial treatment of 2 day in vitro (2DIV) application of Taxol with cRheb 
transfection resulted in significantly greater axonal outgrowth than either the 2DIV Taxol 
application (p<0.01) or the cRheb transfection alone (p<0.01) (Figure 4GG). The combinatorial 
2DIV Taxol treatment with cRheb transfection also yielded significantly higher axonal 
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outgrowth than the combinatorial 3 day in vitro (3DIV) application of Taxol with cRheb 
transfection (p<0.01) (Figure 4GG).  
3DIV application of Taxol alone yielded significantly longer axons than the 
combinatorial treatment of 3DIV application and cRheb transfection (p<0.05) (Figure 4GG). The 
3DIV Taxol application condition also yielded significantly more axonal outgrowth than 2DIV 
application of Taxol alone (p<0.01) (Figure 4GG). There was no significant difference between 
the combinatorial treatment of 3DIV application of Taxol with cRheb transfection and cRheb 
transfection alone. 
 
N2a Cell Line: Growth-Inhibitory Substrate 
 In experimental conditions where the N2as were exposed to both laminin and aggrecan, 
the combinatorial treatment of 2DIV Taxol application with cRheb transfection yielded 
significantly more axonal outgrowth than cRheb transfection alone (p<0.01) (Figure 4GG). 
However, there was no significant difference between the combinatorial treatment of 2DIV 
Taxol application with cRheb transfection and 2DIV Taxol application alone. 2DIV application 
of Taxol alone yielded significantly higher axonal outgrowth than the DMSO control group 
(p<0.01) (Figure 4GG). 
 The application of only Taxol 3DIV yielded significantly higher axonal outgrowth than 
all other conditions (Figure 4GG).  This includes the combinatorial treatment of 3DIV Taxol 
application and cRheb transfection. The combinatorial treatment of 3DIV Taxol application with 
cRheb transfection yielded significantly lower axonal outgrowth than cRheb transfection alone 
(p<0.01) as well as the combinatorial treatment control group (p<0.01) (Figure 4GG).  
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N2a Cell Line: Comparison between both substrates  
When comparing axonal outgrowth between the two substrates, in the N2a cell line, the 
3DIV Taxol application in the inhibitory substrate yielded significantly higher axonal outgrowth 
than 3DIV Taxol application in the growth-promoting substrate (p<0.01) as well as the 
combinatorial treatment of 2DIV Taxol with cRheb transfection in the growth-promoting 
substrate (p<0.01) (Figure 4GG). 2DIV Taxol application alone within the inhibitory substrate 
also yielded significantly higher axonal outgrowth than the same condition grown within the 
growth-promoting substrate (p<0.01) (Figure 4GG). 
 
F11 Cell Line: Growth Promoting Substrate 
Within the experimental conditions where the F11 neuronal cell line is exposed to only 
Laminin, the combinatorial treatment of 2DIV Taxol application with cRheb transfection 
significantly decreased axonal outgrowth compared to 2DIV application of Taxol alone (p<0.05) 
(Figure 4GG). There was also no significant difference between this combinatorial treatment and 
cRheb transfection alone. However, the combinatorial 2DIV Taxol application and cRheb 
transfection yielded significantly more axonal outgrowth than 3DIV Taxol application alone 
(p<0.01) (Figure 4GG).  
The combinatorial treatment of 3DIV application of Taxol with cRheb transfection 
yielded significantly longer axons than 3DIV Taxol application alone (p<0.01) (Figure 4GG). 
This combinatorial treatment, however, did not yield a significant difference in axonal outgrowth 
compared to cRheb transfection alone. The combinatorial 3DIV Taxol treatment with cRheb also 
yielded significantly lower axonal outgrowth than 2DIV Taxol treatment alone (p<0.05) (Figure 
4GG). 2DIV Taxol treatment alone resulted in significantly greater axonal outgrowth than 3DIV 
Taxol treatment alone (p<0.01) (Figure 4GG). 
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F11 Cell Line: Growth Inhibitory Substrate 
 Within the experimental conditions where F11s were exposed to both laminin and 
aggrecan, none of the combinatorial conditions were observed to have significantly greater 
axonal outgrowth when compared to the other conditions. Application of Taxol for 3DIV alone 
had significantly greater axonal lengths than both combinatorial conditions (p<0.01) (Figure 
4GG). It also had significantly higher axonal lengths than 2DIV Taxol application alone (p<0.01) 
(Figure 4GG). cRheb transfection alone also yielded significantly higher axonal outgrowths than 
either of the combinatorial conditions (p<0.01) (Figure 4GG).  
 
F11 Cell Line: Comparison between both substrates  
 When comparing the conditions between both substrates, most comparisons showed 
conditions within the growth-promoting substrate yielding significantly greater axonal outgrowth 
than those within the growth-inhibitory substrate. However, the 3DIV Taxol application 
treatment within the inhibitory substrate yielded significantly more axonal outgrowth than both 
combinatorial treatments within the growth-promoting substrates (p<0.01 when compared to 
3DIV Taxol with cRheb; p<0.05 when compared to 2DIV Taxol with cRheb) as well as cRheb 
transfection alone in the growth-promoting substrate (p<0.01) (Figure 4GG). cRheb transfection 
alone within the inhibitory substrate also yielded significantly higher axonal outgrowth than 
3DIV Taxol application alone in the growth-promoting substrate (p<0.01) (Figure 4GG). 
 
N2a Cell Line versus F11 Cell Line 
 The F11 cell line yielded significantly higher axonal outgrowth in the majority of the 
conditions compared to the N2A cell line in both growth-promoting substrate and inhibitory 
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substrate. However, the N2a cell line yielded significantly greater axonal outgrowth with the 





Figure 4 (A-FF). Average axonal outgrowth in each condition. A continued figure. F11 cells (A-P) and N2a cells 
(Q-FF) were grown a total of 4 days in vitro on inhibitory or growth-promoting substrate. The cells were then 
stained with β-tubulin III (red), E-GFP (green) and DAPI (blue). The scale bar is 10 microns. 
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Figure 4 continued (GG). Average axonal outgrowth in each condition. A single asterisk (*) signifies a p-value 
less than 0.05. Two asterisks (**) signify a p-value less than 0.01. Three asterisks (***) signifies the condition is 
significant compared to all other conditions. 
 
Discussion 
2DIV Taxol Application and cRheb Transfection is a potential combinatorial treatment 
One promising finding within this study was the potential of utilizing the combinatorial 
treatment of Taxol 2DIV application with cRheb transfection to further promote neuronal 
regeneration. This combinatorial treatment was shown to significantly increase axonal growth 
within the N2a cell line compared to either treatment alone within the stimulatory condition and 
was significantly better than cRheb transfection alone within the inhibitory condition (Figure 
4GG).  
While the combinatorial treatment did not yield significant differences with 2DIV 
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with the combinatorial treatment could potentially bridge the gap between the two different 
results in the two conditions. ChABC’s ability to promote neuronal regeneration within an 
inhibitory environment has been seen in several studies [14, 34-36]. ChABC removes the 
inhibitory component of CSPG and could therefore counteract the inhibitory effects of aggrecan 
and allow for maximal axonal regeneration when the combinatorial treatment is applied [37].  
 
Cell type may affect response to treatment 
The F11 cell line yielded opposite results when compared to the N2a cell line in the 
combinatorial 2DIV Taxol application with cRheb transfection condition. The combinatorial 
treatment of 2DIV application of Taxol with cRheb transfection yielded significantly lower 
axonal outgrowth than either treatment alone in the inhibitory condition (Figure 4GG). The F11 
cell line also exhibited significantly higher outgrowth in most conditions when compared to the 
N2a cell line, with the N2a cell line only yielding significantly higher axonal outgrowth in the 
3DIV Taxol application alone condition across both substrates (Figure 4GG). 
This suggests that cell type plays a role in how effective treatments are in promoting 
axonal regeneration. The N2a neuronal cells are neuroblastoma cells derived from the neural 
crest of mice [76]. The F11 neuronal cells, in contrast, are hybrid cells consisting of mice 
neuroblastoma fused with embryonic rat dorsal-root ganglion neurons [77]. Both sets of 
chromosomes are retained in F11 cells and proteins from both animals within the hybrid are 
synthesized [77]. This may play a factor in why F11 cells respond differently to the 
combinatorial treatment than N2a cells. 
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3DIV Taxol Application Alone is another potential treatment for CNS trauma 
Another promising finding within the study was the application of Taxol for 3DIV alone 
yielded significantly greater axonal outgrowth in both cell types in the inhibitory condition 
(Figure 4GG). In N2as, 3DIV Taxol application resulted in axons significantly longer compared 
to every other experimental condition as well as control conditions (Figure 4GG). In F11s, 3DIV 
Taxol application was observed to have significantly higher axonal outgrowth than all 
experimental conditions (Figure 4GG). Application of 3 nM Taxol for 3DIV is therefore a 
potential method to promote neuronal regeneration after trauma to the CNS. Further studies can 
also potentially elongate the time neurons are exposed to Taxol past 3DIV, which may further 
promote axonal growth and regeneration. A potential setback to this method is that 
overpopulation of cells may occur, making collection of data difficult. 
 
Taxol’s ability to promote regeneration may be dependent upon presence of trauma 
 In the N2a cell line, Taxol produces greater axonal outgrowth within the inhibitory 
substrate than in the growth-promoting substrate. Growth is normally significantly lower on 
inhibitory substrates.  Here, 3DIV Taxol application alone on the inhibitory substrate yielded 
significantly higher N2a axonal outgrowth than in the growth-promoting substrate (Figure 4GG). 
This same trend was mirrored with 2DIV Taxol application alone (Figure 4GG). 2DIV Taxol 
application by itself produced significantly more axonal outgrowth in the inhibitory substrate 
than in the growth-promoting substrate (Figure 4GG). In F11s, this trend is also seen with the 
application of Taxol alone 3DIV yielding significantly greater axonal outgrowth compared to 
both combinatorial conditions in the inhibitory substrate (Figure 4GG). This is in contrast to the 
growth-promoting substrate, in which 3DIV Taxol application yielded either no significant 
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difference in axonal outgrowth or significantly less axonal outgrowth when compared to those 
same conditions.  
 
3DIV Taxol with cRheb Transfection is least effective at promoting axonal regeneration 
The combinatorial treatment of 3-DIV application of Taxol with cRheb transfection 
resulted in significantly reduced axonal outgrowth in both cell types in the inhibitory condition 
(Figure 4GG). This may be due to the time of Taxol application being concurrent with cRheb 
transfection. As the neuronal cells are taking in the plasmid with cRheb at the same time as they 
are being exposed to Taxol, the stress on the neurons may have exceeded the neuron’s limit and 
thus, lower axonal outgrowth was observed.  
The use of fidgetin knockdown may be a viable alternative to Taxol lessen the stress 
placed on cells and maximize the neuronal regeneration that is capable with combinatorial 
treatments. Fidgetin is a protein that is naturally produced within cells and cleaves microtubules 
that are unstable [72]. Knocking down the gene for fidgetin would, therefore, serve the same 
purpose as Taxol and stabilize microtubules within neurons. Fidgetin knockdown alone has been 
shown previously to improve neuronal regeneration by Matamoros et al [21]. 
A different method of transfection may also yield more promising results. cRheb 
transfection alone had yielded significantly lower axonal outgrowth than the transfection control 
within the both substrates with F11 cell line and within the inhibitory substrate in the N2a cell 
line (Figure 4GG). Transfection efficiency was also lower than expected during the study. 
Utilizing a viral vector to transduce the cRheb gene as opposed to transfection may improve 
cRheb’s effects on axonal regeneration as well as have a higher efficiency. An alternate method 
of transfection may also improve efficiency. 
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Overall, the combinatorial treatment of 2DIV application of Taxol with cRheb 
transfection along with application of 3DIV Taxol application alone are promising methods to 
promote axonal regeneration following CNS trauma. Further studies that apply these conditions 
in vivo could further solidify either treatment as future therapeutic methods for CNS injury if the 
results are the same as observed in this study and help increase the quality of life of individuals 




CHAPTER THREE: META-ANALYSIS COMPARISON OF TWO NEURONAL 




 As neurons lack the ability to regenerate, CNS trauma commonly leads to neurons that 
are permanently damaged. This may result in permanent motor damage, cognitive damage, or 
both and decrease the overall quality of life of an individual [1]. Therefore, the search for a 
viable method to promote axonal regeneration after CNS trauma is crucial. Two methods used 
within the scientific community to promote axonal regeneration are upregulation of the mTOR 
pathway and microtubule stabilization. 
 The upregulation of the mTOR pathway is one method of increasing the intrinsic growth 
capacity of neurons, which in turn promotes axonal elongation and regeneration following 
trauma. It has been shown by Park et al. and Liu et al. that the intrinsic growth capacity of a 
neuron diminishes as the neuron matures from embryonic to adult and due to injury to the neuron 
[11, 12]. P-S6 signals were observed to be weaker in adult neurons compared to embryonic 
neurons and in injured neurons compared to non-injured neurons [11, 12]. The mTOR pathway is 
a target of neuronal regeneration because the mTOR pathway is a signaling pathway that 
functions to regulate cellular growth, metabolism, and proliferation [49]. Proteins targeted along 
this pathway for neuronal regeneration include PTEN, TSC, Rheb, S6K1, and AKT. Proteins 
outside the pathway that also upregulate the mTOR pathway are SOCS3, HDAC5, and 
melanopsin. 
 PTEN, SOCS3, and TSC are all inhibited or suppressed in order to upregulate the mTOR 
pathway [11, 12, 18-20, 54]. PTEN typically downregulates the mTOR pathway as it is a tumor 
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suppressor [51]. SOCS3 typically suppresses mTOR reactivation following neuronal injury [18, 
62]. TSC is a protein that prevents the activation of Rheb, therefore preventing an activated Rheb 
from activating the mTORC1 protein [49]. Rheb, in contrast, is targeted in neuronal regeneration 
through the use of constitutively active Rheb (cRheb), a mutant Rheb that is designed to be 
constantly activated in order to continuously upregulate mTORC1 [52, 57]. Activation of S6K1 
promotes protein translation and is targeted for axonal regeneration [20]. AKT inhibits TSC and 
thus, its activation allows for the activation for mTORC1 [16, 49]. Two other methods of 
upregulating the mTOR pathway are utilizing HDAC5’s phosphorylation state to activate the 
mTOR pathway and overexpression of melanopsin within retinal ganglion cells to upregulate 
mTORC1 [15, 17]. 
 Another method of promoting axonal regeneration is microtubule stabilization. 
Microtubule stabilization within neurons is accomplished using chemotherapeutic drugs, such as 
Taxol and epothilones B (epoB) and D (epoD) [22-24, 71]. Chemotherapeutic drugs have been 
shown to successfully promote axonal regeneration in several studies as they prevent the 
depolymerization of microtubules, promoting elongation instead [22-24, 71]. This allows for 
axons to regenerate following injury [22-24, 71]. Another method of microtubule stabilization 
used in neuronal regeneration that has been shown to increase regeneration in a study conducted 
by Matamoros et al. is the knockdown of fidgetin, a protein within the cell that cleaves unstable 
microtubules [21, 72]. Two other methods that induce microtubule stabilization are 
overexpression of FGF13, a protein that typically stabilizes microtubules in the brain during 
early development, and the administration of the Metformin, a drug that typically lowers glucose 
but also stabilizes microtubules [25, 26]. 
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 This study aims to compare the two methods of promoting neuronal regeneration and see 
if there are any significant differences in the effects each method has on axonal regeneration. 
Based on the results of the study testing the combinatorial effect of cRheb and Taxol on axonal 
regeneration in vitro, I predict that microtubule stabilization would be more effective at 
enhancing neuronal regeneration than the upregulation of mTOR. The results of the 
combinatorial study showed that Taxol application alone for 3DIV yielded significantly higher 
axonal outgrowth than all other conditions in the N2a cell line in vitro. This may indicate 
microtubule stabilization, which is the mechanism by which Taxol promotes neuronal 
regeneration, would more significantly enhance axonal regeneration than upregulation of mTOR. 
 
Materials and Methods 
Literature Search and Selection 
 A literature search was conducted to collect studies utilizing either upregulation of the 
mTOR pathway or microtubule stabilization as a method for promotion neuronal regeneration. 
The electronic databases used in the search were PubMed and the University of Central Florida 
Libraries database. Keywords and terms used to search for studies in the electronic databases that 
have potential for inclusion in the meta-analysis were “Central Nervous System”, “CNS”, 
“microtubule stabilization”, “mTOR”, “neuronal regeneration”, and “axonal regeneration”. 
 The studies were then filtered and studies chosen for inclusion were based on the criteria 
that (1) the study focuses on CNS injury and CNS neuronal regeneration, (2) the study was 
conducted in vivo, and (3) the study included measurements pertaining to axonal outgrowth, 
including average distance an axon regenerates past the lesion and number of regenerating fibers 
versus distance from injury site. 
 37 
After application of the criteria, five studies utilizing microtubule stabilization and ten 
studies in which upregulation of mTOR was used were chosen for this meta-analysis (Table 1).  
 
First Author (Year) Method CNS Injury Animal Time (Weeks) 
Upregulation of mTOR  
Wu (2015) cRheb ST (T7) Rats 4 
Park (2008) PTEN Deletion 
TSC Deletion 
ONC Mice 2, 4 
Sun (2011) PTEN and SOCS3 
co-deletion 
ONC Mice 2, 4 
Smith (2009) SOCS3 Deletion ONC Mice 2 
Leibinger (2019) PTEN Knockout ONC Mice 3 
Pita-Thomas (2019) HDAC5 Expression ONC Mice 2 
Li (2016) Melanopsin 
Modulation 
ONC Mice 2 
Yang (2014) S6K1 Activation 
SOCS3 Deletion 
ONC Mice  
Huang (2019) PTEN Knockout ONC Mice 2 




Sengottivel (2011) Taxol ONC 
Lens Injury 
Rats 2 
Ruschel (2015) EpoB Spinal Cord Dorsal 
Hemisection 
Rats 4 
Matamoros (2011) Fidgetin 
Knockdown 
Dorsal Root Crush Rats 4 
Li (2018) Lentivirus-FGF13 SL (T9) Rats 2 
Wang (2020) Metformin SL (T9) Rats 2 
 
Table 1. Studies utilized in the meta-analysis. Data from ten studies utilizing mTOR upregulation and five studies 
utilizing microtubule stabilization was analyzed. All studies contained data that measured axonal counts versus 
distance from the lesion or the average axonal length from the lesion. Abbreviations: ST=Spinal Transection; 
ONC=Optic Nerve Crush; SL=Spinal Laminectomy.  
 
Data Collection 
 Data was extracted straight from studies when values were explicitly stated. In studies in 
which values were not explicitly stated and were only shown in graphs, data was extracted using 
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 Data from the studies were classified as yielding High, Medium, or Low Axonal 
Regeneration. Operational definitions were devised for high, medium, and low axonal 
regeneration in order to properly compare studies that collected average axonal distance from the 
lesion site to studies that collected axon counts versus distance from lesions sites. 
 The studies that collected axon counts versus distance from lesion sites included all the 
studies utilizing mTOR upregulation as well as two microtubule stabilization studies, 
Sengottuvel et al. and Matamoros et al.[11, 14-21, 24, 80, 81]. For these studies, (1) high axonal 
regeneration was categorized as the number of axons at a distance equal to or greater than 1000 
μm beyond the lesion, (2) medium axonal regeneration consisted of the number of axons counted 
between 500 μm to 999 μm beyond the lesion, and (3) low axonal regeneration was the number 
of axons counted between 0 μm to 499 μm beyond the lesion (Table 2). After classification of 
axon counts in one of the three categories, the axon counts per category were divided by the total 
axons counted for each study, resulting in the proportion of high, medium, and low axonal 
regeneration of each study. 
 The studies that measured average axonal distance from lesion include Ruschel et al., 
Wang et al., and Li et al.[22, 25, 26]. For these studies, an average axonal distance (1) high 
axonal regeneration was categorized as having an average axonal distance from the lesion equal 
to or greater than 1000 μm between, (2) medium axonal regeneration consisted of an average 
axonal distance from the lesion between 500 μm to 999 μm, and (3) low axonal regeneration 
included studies with an average axonal distance of 0 μm to 499 μm from the lesion (Table 2). 
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After classification of each study’s data as low, medium, or high axonal regeneration, the study 
was given an overall value of 1 in one of the classifications based on what classification its 
measured average distance from the lesion was. The remaining two categories received a value 
of 0.  
 Data analysis was performed using SPSS software. Different statistical tests were utilized 
based on the distribution of the data of the experimental and control groups. For data that was 
normally distributed, a one-way ANOVA and independent T-Tests were used to establish 
significance. For data that was not normally distributed (nonparametric) as well as for comparing 
between normally-distributed data and nonparametric data, Kruskal-Wallis tests and Mann-







Operational Definition References 
High 1. Number of axon counts equal to or greater 
than 1000 µm beyond lesion   
2. Average distance beyond lesion equal to or 
greater than 1000 µm  
[11, 14-21, 24, 79, 80]  
 
[22, 25, 26]  
Medium 1. Number of axon counts between 500 µm to 
999 µm beyond lesion      
2. Average distance beyond lesion between 500 
µm to 999 µm  
[11, 14-21, 24, 79, 80]  
 
[22, 25, 26]  
Low 1. Number of axon counts between 0 µm to 499 
µm beyond lesion  
2. Average distance beyond lesion between 0 
µm to 499 µm  
[11, 14-21, 24, 79, 80]  
 
[22, 25, 26]  
Table 2. Operational definitions for High, Medium, and Low axonal regeneration. Two different methods of 
measuring axonal outgrowth from the CNS lesion were utilized in the studies. To compare the data of the two 
methods, data was classified into High, Medium, or Low axonal regeneration based on the definitions listed in the 
table. The references each definition was applied to are also listed in the table. 
 
Results 
Axonal regeneration at two weeks post-injury 
 Experimental groups utilizing mTOR upregulation yielded significantly higher 
proportions of high axonal regeneration and medium axonal regeneration than their respective 
mTOR upregulation control groups (both p<0.01) (Figure 5). The mTOR upregulation control 
had significantly greater low axonal regeneration proportions compared to the mTOR 
upregulation experimental group (p<0.01) (Figure 5). In contrast, there was no significance 
between the microtubule stabilization experimental proportions and the microtubule stabilization 
control proportions. There was also no significance between high, medium, or low axonal 
regeneration proportions within the microtubule stabilization experimental group. 
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 When comparing between the mTOR upregulation experimental group and the 
microtubule stabilization experimental group, mTOR upregulation’s proportion of medium 
axonal regeneration was significantly higher than the microtubule stabilization proportion of 
medium axonal regeneration (p<0.01) (Figure 5). Also noted was that the mTOR experimental 
group was normally distributed. All other groups, including the microtubule stabilization 
experimental group, were nonparametric.  
 
Axonal regeneration at three to four weeks post-injury 
 At three to four weeks post injury, there was no significance between the mTOR 
upregulation experimental or control groups. This lack of significance is mirrored between the 
microtubule stabilization experimental and control groups. There was also no significant 
differences between the proportions of high, medium, and low axonal regeneration within the 
mTOR upregulation experimental group. Within the microtubule stabilization experimental 
group, the proportion of high axonal regeneration was significantly lower than the proportion of 
low axonal regeneration (p<0.05) (Figure 5). 
 Comparisons between both the mTOR upregulation and microtubule stabilization 
experimental groups yielded only one significant difference, with the proportion of low axonal 
regeneration within microtubule stabilization being significantly greater than the proportion of 
mTOR upregulation’s medium axonal regeneration (p<0.05) (Figure 5). At three to four weeks, 
both mTOR upregulation and microtubule stabilization were normally distributed while their 
respective controls were nonparametric.  
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Axonal Regeneration at two weeks post-injury versus three to four weeks post-injury 
 There were no significant differences between the proportions of high, medium, and low 
axonal regeneration in mTOR upregulation at two weeks post injury versus three to four weeks 
post injury. The same trend is mirrored within the microtubule stabilization at two weeks post 
injury versus three to four weeks post injury. Significance was observed when comparing the 
proportions of mTOR upregulation at two weeks post injury to the proportions of microtubule 
stabilization at three to four weeks. mTOR upregulation experimental proportions for high, 
medium, and low axonal regeneration at two weeks post injury were each significantly higher 
than the microtubule stabilization proportion of high axonal regeneration at three to four weeks 
post injury (Figure 5). Microtubule stabilization proportion of low axonal regeneration at three to 
four weeks was also significantly higher than mTOR proportions of low and high axonal 
regeneration at two weeks post injury (Figure 5). The proportion of mTOR upregulation’s low 
axonal regeneration at two weeks post injury was also significantly greater than microtubule 
stabilization’s proportion of medium axonal regeneration at three to four weeks post injury 
(Figure 5). Comparisons between the high, medium, and low proportions of microtubule 
stabilization at two weeks and mTOR upregulation’s proportions at three to four weeks yielded 
no significant differences. 
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Figure 5. Axon Regeneration Index for experimental and control conditions. Either axonal counts or average 
axon distance from the lesion were classified as Low, Medium, or High axonal regeneration. Proportions of each 
classification per study were then calculated and statistical analysis was conducted.  Errors bars represent SEM. A 
single asterisk signifies a p-value less than 0.05. Two asterisks signify a p-value less than 0.01. 
 
Discussion 
 Data from published studies utilizing either mTOR upregulation or microtubule 
stabilization to promote axonal regeneration were analyzed and compared. Results indicate that 
mTOR upregulation may be more effective at promoting axonal regeneration. This is seen at two 
weeks post injury in which the proportions of high and medium axonal growth for the 
experimental group within mTOR upregulation were significantly higher than the high and 




























































upregulation control group’s low axonal regeneration proportion was also significantly higher 
than the mTOR upregulation experimental group’s proportion of low axonal regeneration (Figure 
5). This illustrates that mTOR upregulation resulted in axonal regeneration farther from the 
lesion. 
 In contrast, microtubule stabilization overall resulted in no significant differences 
between experimental proportions of high, medium, and low axonal regeneration and the 
proportions of the control. Therefore, microtubule stabilization may be less effective in 
promoting axonal regeneration.  
 In addition, when directly comparing mTOR upregulation and microtubule stabilization, 
mTOR upregulation at two weeks yielded significantly higher low, medium, and high axonal 
regeneration proportions than microtubule stabilization’s high axonal regeneration proportion at 
three to four weeks post injury (Figure 5). The microtubule stabilization low axonal regeneration 
proportion at three to four weeks post injury was also significantly higher than mTOR 
upregulation’s low and high axonal regeneration proportions at two weeks post injury (Figure 5). 
This shows that mTOR upregulation yielded axonal regeneration that traveled farther from the 
lesion in a shorter time period than microtubule stabilization.  
These results may also indicate that mTOR upregulation’s effects in promoting axonal 
regeneration begin earlier than microtubule stabilization’s effects. This is also supported by the 
different distributions of data of the experimental groups when comparing between the two time 
points of two weeks and three to four week post injury.  At two weeks post injury, only the 
mTOR upregulation experimental group had normally distributed data. Microtubule 
stabilization’s experimental group mirrored the two controls at having data that was 
nonparametric. At three to four weeks post injury, both mTOR upregulation’s experimental 
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group and microtubule stabilization’s experimental group had normally distributed data while the 
controls continued to be nonparametric. This switch in distribution of microtubule stabilization 
data between the two time periods to mirror that of mTOR upregulation experimental group’s 
distribution and oppose that of the controls may imply that microtubule stabilization’s promotion 
of regeneration may have been observed after the two weeks following injury. Still, the long-
term regenerative potential is important to consider as reaching the target is the goal. 
Upregulating mTOR seems to promote faster growth, but more research will have to be 
conducted to determine the long-term growth potential of each method. 
Overall, mTOR upregulation is shown to be more effective at promoting axonal 
regeneration than microtubule stabilization within this meta-analysis. However, the lower 
number of studies utilizing microtubule stabilization as the method of promotion of axonal 
regeneration within this meta-analysis may play a role in the lack of significant results (Table 1). 
Therefore, while mTOR upregulation is indicated to be a more viable method of axonal 
promotion by the results of this meta-analysis, more studies should be performed testing 
microtubule stabilization’s effects on neuronal regeneration. A wider pool of results for the 
method of microtubule stabilization may alter the results seen in this meta-analysis, potentially 




CHAPTER FOUR: CONCLUSION 
 
Discussion 
The effects of two methods of CNS neuronal regeneration promotion, mTOR signaling 
pathway upregulation and microtubule stabilization, were explored. Aim 1 had the goal of testing 
if a combinatorial treatment of both methods yields more axonal regeneration than either method 
by itself. Taxol was used for microtubule stabilization, while cRheb transfection was used to 
upregulate the mTOR pathway. Both have been shown to enhance axonal regeneration in the 
CNS alone [14, 24]. Our hypothesis that the combinatorial treatment would yield significantly 
more axonal outgrowth was supported by the combinatorial treatment of 2DIV Taxol application 
with cRheb transfection, yielding significantly greater axonal outgrowth than either alone. 
Aim 2 was a meta-analysis comparing the effectiveness of the two methods of promotion 
of neuronal regeneration, mTOR upregulation and microtubule stabilization. It was expected, 
based off the results of the combinatorial study, that microtubule stabilization would yield 
significantly more axonal regeneration than upregulation of the mTOR pathway. However, this 
hypothesis was proven incorrect as upregulation of the mTOR pathway produced significantly 
higher axonal regeneration past the lesion than microtubule stabilization.  
 
The higher potential of mTOR upregulation in promoting neuronal regeneration 
 The meta-analysis results indicated that upregulation of the mTOR pathway is more 
effective at promoting axonal regeneration than microtubule stabilization (Figure 5). However, 
the opposite was observed in the combinatorial study where 3DIV Taxol application alone 
yielded significantly higher axonal outgrowth than all other experimental conditions, including 
cRheb transfection alone, in the inhibitory substrate across both cell lines (Figure 4GG). This 
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may be due to the method of cRHeb transfection utilized in the combinatorial study. The method 
of cRheb transfection had produced observable low transfection efficiency, and cRheb 
transfection control groups yielded higher axonal outgrowth than the cRheb transfection 
experimental group. An alternate method of introducing cRheb into the neuronal cells, possibly 
through a viral vector as opposed to transfection, may yield more axonal outgrowth.  
 Another factor that may explain why results of the combinatorial study and the meta-
analysis oppose one another is the environment in which the studies were carried out. The meta-
analysis utilized studies carried out in vivo while the combinatorial study was conducted in vitro. 
In vivo studies involve many more external barriers that neurons have to overcome in order to 
regenerate past the lesion, such as microglia, CSPGs, and macrophages. The combinatorial 
study, in contrast, had only CSPGs as the main barrier to regeneration with the use of aggrecan. 
In addition, transfecting the plasmid may have damaged the cells. mTOR upregulation may have 
been better suited to overcome the many barriers within the in vivo studies, resulting in mTOR 
upregulation being significantly more effective at promoting axonal regeneration than 
microtubule stabilization in the meta-analysis. Overall, the results of the meta-analysis indicate 
that efforts should be focused on further testing mTOR upregulation in promoting axonal 
regeneration, as it is the more promising method of axonal regeneration in vivo. 
 
Microtubule stabilization’s promotion of axonal regeneration is time-dependent 
 One similarity seen in results of both the combinatorial study and the meta-analysis is 
that microtubule stabilization effects in promoting axonal regeneration may be time-dependent. 
Application of microtubule stabilization to the CNS injury for a longer period of time yielded 
more axonal outgrowth. This is seen in the combinatorial study in which 3DIV Taxol application 
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alone resulted in significantly increased axonal outgrowth compared to 2DIV Taxol application 
alone (Figure 4GG). In the meta-analysis, the change in distribution of the microtubule 
stabilization groups data distribution from nonparametric at two weeks post injury mirroring the 
control groups to a normal data distribution at three to four weeks post injury mirroring that of 
the mTOR experimental group indicates that microtubule stabilization’s effects in neuronal 
regeneration became observable after two weeks post injury. Therefore, elongating the time 
microtubule stabilization is applied to a CNS injury may further enhance axonal regeneration. 
 
Combinatorial treatment of 2DIV Taxol Application with cRheb transfection is promising 
 The potential for a novel method of neuronal regeneration combining microtubule 
stabilization and upregulation of mTOR was shown in the combinatorial study. The 
combinatorial treatment of 2DIV Taxol application with cRheb transfection yielded significantly 
greater axonal outgrowth than either treatment alone in N2as in the growth-promoting substrate 
(Figure 4GG). It also yielded significantly higher axonal outgrowth than cRheb transfection 
alone in the inhibitory substrate in the N2a cell line (Figure 4GG). This combinatorial method 
has the potential to enhance neuronal regeneration past the capabilities of either method by itself 
and may be a viable treatment option for CNS injury after more research is conducted. 
 
Future Directions 
More studies utilizing microtubule stabilization should be conducted 
A potential reason why microtubule stabilization was shown to be significantly less 
effective at promoting neuronal regeneration in the meta-analysis in opposition to the results of 
the combinatorial study is because of the small data pool from which the microtubule 
stabilization group’s data was derived from. Only five studies utilizing microtubule stabilization 
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met the inclusion criteria while ten studies were used in the meta-analysis for mTOR 
upregulation (Table 1). This large difference in data pool size may result in the microtubule 
stabilization results not being fully representative of the full potential of microtubule stabilization 
at promoting axonal regeneration. 
To ensure the full potential of microtubule stabilization as a promoter of axonal 
regeneration is discovered, more studies testing microtubule stabilization in promoting axonal 
regeneration should be conducted. In the search for studies to include in the meta-analysis there 
was drastically less studies focused on using microtubule stabilization in axonal regeneration 
than those that use mTOR upregulation to promote axonal regeneration. The combinatorial 
study’s results have indicated that microtubule stabilization has the potential to significantly 
enhance neuronal regeneration (Figure 4GG). More studies testing microtubule stabilization will 
allow for a more accurate comparison between the effectiveness of that method of neuronal 
regeneration and upregulation of mTOR in promoting axonal regeneration. 
 
Further testing of the combinatorial treatment should be undertaken 
 A study further testing the combinatorial treatment of both Taxol application and cRheb 
transfection on axonal regeneration in vitro was previously planned but was interrupted due to 
the COVID-19 pandemic. This study aimed to test the combinatorial treatment in aggrecan spots, 
in which the environment is an inhibitory gradient, with the spot being stimulatory at the center 
and becoming increasingly inhibitory towards the rim of the spot. This environment more closely 
mimics the glial scar environment in vivo [29, 33]. Quantification of axons crossing the 
inhibitory rim into the growth-promoting substrate surrounding the spots would indicate the 
extent of axonal regeneration the combinatorial treatment is capable of. This study should be 
undertaken in the future in order to continue investigating the potential of a combinatorial 
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treatment for CNS injury. To further see if a combinatorial treatment is viable, studies applying a 
combinatorial treatment in vivo would yield even stronger results that may indicate combinatorial 
treatment as a feasible mechanism for CNS injury treatment.  
 CNS injury currently results in long-term or permanent damage to an individual’s motor 
abilities, resulting in a drastic decrease in the individual’s quality of life. The inability for axons 
to regenerate following CNS injury is the main reason for the detrimental effects of CNS injury. 
This is why the search for a viable method of therapy to promote axonal regeneration and allow 
for recovery following CNS injury is important. Research using the upregulation of the mTOR 
pathway, microtubule stabilization, a combinatorial treatment, or another method of promoting 
axonal regeneration should be continued until a successful method is found and CNS injury is no 
longer a permanent impairment. 




1. Shoichet, M.S., et al., Strategies for Regeneration and Repair in the Injured Central 
Nervous System, in Indwelling Neural Implants: Strategies for Contending with the In 
Vivo Environment, W.M. Reichert, Editor. 2008: Boca Raton (FL). 
2. Fries, P., A mechanism for cognitive dynamics: neuronal communication through 
neuronal coherence. Trends Cogn Sci, 2005. 9(10): p. 474-80. 
3. Donnelly, D.J. and P.G. Popovich, Inflammation and its role in neuroprotection, axonal 
regeneration and functional recovery after spinal cord injury. Exp Neurol, 2008. 209(2): 
p. 378-88. 
4. Schwab, M.E. and P. Caroni, Oligodendrocytes and CNS myelin are nonpermissive 
substrates for neurite growth and fibroblast spreading in vitro. J Neurosci, 1988. 8(7): p. 
2381-93. 
5. Silver, J. and J.H. Miller, Regeneration beyond the glial scar. Nat Rev Neurosci, 2004. 
5(2): p. 146-56. 
6. Center, N.S.C.I.S. Spinal Cord Injury Facts and Figures at a Glance. [Webpage] 2020  
[cited 2020 October 27]. 
7. McKerracher, L., et al., Identification of myelin-associated glycoprotein as a major 
myelin-derived inhibitor of neurite growth. Neuron, 1994. 13(4): p. 805-11. 
8. Savio, T. and M.E. Schwab, Lesioned corticospinal tract axons regenerate in myelin-free 
rat spinal cord. Proc Natl Acad Sci U S A, 1990. 87(11): p. 4130-3. 
9. Horn, K.P., et al., Another barrier to regeneration in the CNS: activated macrophages 
induce extensive retraction of dystrophic axons through direct physical interactions. J 
Neurosci, 2008. 28(38): p. 9330-41. 
10. S, R.y.C., Degeneration and regeneration of the nervous system. 1928, London: Oxford 
UP. 
11. Park, K.K., et al., Promoting axon regeneration in the adult CNS by modulation of the 
PTEN/mTOR pathway. Science, 2008. 322(5903): p. 963-6. 
12. Liu, K., et al., PTEN deletion enhances the regenerative ability of adult corticospinal 
neurons. Nat Neurosci, 2010. 13(9): p. 1075-81. 
13. Al-Ali, H., et al., The mTOR Substrate S6 Kinase 1 (S6K1) Is a Negative Regulator of 
Axon Regeneration and a Potential Drug Target for Central Nervous System Injury. J 
Neurosci, 2017. 37(30): p. 7079-7095. 
14. Wu, D., et al., Expressing Constitutively Active Rheb in Adult Neurons after a Complete 
Spinal Cord Injury Enhances Axonal Regeneration beyond a Chondroitinase-Treated 
Glial Scar. J Neurosci, 2015. 35(31): p. 11068-80. 
15. Li, S., et al., Promoting axon regeneration in the adult CNS by modulation of the 
melanopsin/GPCR signaling. Proc Natl Acad Sci U S A, 2016. 113(7): p. 1937-42. 
16. Miao, L., et al., mTORC1 is necessary but mTORC2 and GSK3beta are inhibitory for 
AKT3-induced axon regeneration in the central nervous system. Elife, 2016. 5: p. 
e14908. 
17. Pita-Thomas, W., et al., HDAC5 promotes optic nerve regeneration by activating the 
mTOR pathway. Exp Neurol, 2019. 317: p. 271-283. 
 52 
18. Smith, P.D., et al., SOCS3 deletion promotes optic nerve regeneration in vivo. Neuron, 
2009. 64(5): p. 617-23. 
19. Sun, F., et al., Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. 
Nature, 2011. 480(7377): p. 372-5. 
20. Yang, L., et al., The mTORC1 effectors S6K1 and 4E-BP play different roles in CNS axon 
regeneration. Nat Commun, 2014. 5: p. 5416. 
21. Matamoros, A.J., et al., Knockdown of Fidgetin Improves Regeneration of Injured Axons 
by a Microtubule-Based Mechanism. J Neurosci, 2019. 39(11): p. 2011-2024. 
22. Ruschel, J., et al., Axonal regeneration. Systemic administration of epothilone B 
promotes axon regeneration after spinal cord injury. Science, 2015. 348(6232): p. 347-
52. 
23. Sandner, B., et al., Systemic epothilone D improves hindlimb function after spinal cord 
contusion injury in rats. Exp Neurol, 2018. 306: p. 250-259. 
24. Sengottuvel, V., et al., Taxol facilitates axon regeneration in the mature CNS. J Neurosci, 
2011. 31(7): p. 2688-99. 
25. Li, J., et al., Lentivirus Mediating FGF13 Enhances Axon Regeneration after Spinal Cord 
Injury by Stabilizing Microtubule and Improving Mitochondrial Function. J 
Neurotrauma, 2018. 35(3): p. 548-559. 
26. Wang, H., et al., Metformin Promotes Axon Regeneration after Spinal Cord Injury 
through Inhibiting Oxidative Stress and Stabilizing Microtubule. Oxid Med Cell Longev, 
2020. 2020: p. 9741369. 
27. McKeon, R.J., et al., Reduction of neurite outgrowth in a model of glial scarring 
following CNS injury is correlated with the expression of inhibitory molecules on reactive 
astrocytes. J Neurosci, 1991. 11(11): p. 3398-411. 
28. Pindzola, R.R., C. Doller, and J. Silver, Putative inhibitory extracellular matrix 
molecules at the dorsal root entry zone of the spinal cord during development and after 
root and sciatic nerve lesions. Dev Biol, 1993. 156(1): p. 34-48. 
29. Tom, V.J., et al., Studies on the development and behavior of the dystrophic growth cone, 
the hallmark of regeneration failure, in an in vitro model of the glial scar and after spinal 
cord injury. J Neurosci, 2004. 24(29): p. 6531-9. 
30. Prinjha, R., et al., Inhibitor of neurite outgrowth in humans. Nature, 2000. 403(6768): p. 
383-4. 
31. Schwab, M.E. and S.M. Strittmatter, Nogo limits neural plasticity and recovery from 
injury. Curr Opin Neurobiol, 2014. 27: p. 53-60. 
32. Shibata, A., et al., Unique responses of differentiating neuronal growth cones to 
inhibitory cues presented by oligodendrocytes. J Cell Biol, 1998. 142(1): p. 191-202. 
33. Davies, S.J., et al., Robust regeneration of adult sensory axons in degenerating white 
matter of the adult rat spinal cord. J Neurosci, 1999. 19(14): p. 5810-22. 
34. Barritt, A.W., et al., Chondroitinase ABC promotes sprouting of intact and injured spinal 
systems after spinal cord injury. J Neurosci, 2006. 26(42): p. 10856-67. 
35. Tom, V.J. and J.D. Houle, Intraspinal microinjection of chondroitinase ABC following 
injury promotes axonal regeneration out of a peripheral nerve graft bridge. Exp Neurol, 
2008. 211(1): p. 315-9. 
36. Busch, S.A., et al., Overcoming macrophage-mediated axonal dieback following CNS 
injury. J Neurosci, 2009. 29(32): p. 9967-76. 
 53 
37. Yiu, G. and Z. He, Glial inhibition of CNS axon regeneration. Nat Rev Neurosci, 2006. 
7(8): p. 617-27. 
38. Lang, B.T., et al., Modulation of the proteoglycan receptor PTPsigma promotes recovery 
after spinal cord injury. Nature, 2015. 518(7539): p. 404-8. 
39. Lacroix, S., et al., Delivery of hyper-interleukin-6 to the injured spinal cord increases 
neutrophil and macrophage infiltration and inhibits axonal growth. J Comp Neurol, 
2002. 454(3): p. 213-28. 
40. Noble, L.J., et al., Matrix metalloproteinases limit functional recovery after spinal cord 
injury by modulation of early vascular events. J Neurosci, 2002. 22(17): p. 7526-35. 
41. MacMicking, J.D., et al., Elevated secretion of reactive nitrogen and oxygen 
intermediates by inflammatory leukocytes in hyperacute experimental autoimmune 
encephalomyelitis: enhancement by the soluble products of encephalitogenic T cells. J 
Exp Med, 1992. 176(1): p. 303-7. 
42. Colton, C.A. and D.L. Gilbert, Production of superoxide anions by a CNS macrophage, 
the microglia. FEBS Lett, 1987. 223(2): p. 284-8. 
43. Huber, A.B., et al., Patterns of Nogo mRNA and protein expression in the developing and 
adult rat and after CNS lesions. J Neurosci, 2002. 22(9): p. 3553-67. 
44. Chivatakarn, O., et al., The Nogo-66 receptor NgR1 is required only for the acute growth 
cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. J 
Neurosci, 2007. 27(27): p. 7117-24. 
45. Nash, M., et al., Central nervous system regeneration inhibitors and their intracellular 
substrates. Mol Neurobiol, 2009. 40(3): p. 224-35. 
46. Fruttiger, M., et al., Crucial role for the myelin-associated glycoprotein in the 
maintenance of axon-myelin integrity. Eur J Neurosci, 1995. 7(3): p. 511-5. 
47. Trapp, B.D., Myelin-associated glycoprotein. Location and potential functions. Ann N Y 
Acad Sci, 1990. 605: p. 29-43. 
48. Kerschensteiner, M., et al., In vivo imaging of axonal degeneration and regeneration in 
the injured spinal cord. Nat Med, 2005. 11(5): p. 572-7. 
49. Laplante, M. and D.M. Sabatini, mTOR signaling at a glance. J Cell Sci, 2009. 122(Pt 
20): p. 3589-94. 
50. Curcio, M. and F. Bradke, Axon Regeneration in the Central Nervous System: Facing the 
Challenges from the Inside. Annu Rev Cell Dev Biol, 2018. 34: p. 495-521. 
51. Song, M.S., L. Salmena, and P.P. Pandolfi, The functions and regulation of the PTEN 
tumour suppressor. Nat Rev Mol Cell Biol, 2012. 13(5): p. 283-96. 
52. Long, X., et al., Rheb binds and regulates the mTOR kinase. Curr Biol, 2005. 15(8): p. 
702-13. 
53. Jacinto, E., et al., Mammalian TOR complex 2 controls the actin cytoskeleton and is 
rapamycin insensitive. Nat Cell Biol, 2004. 6(11): p. 1122-8. 
54. Zukor, K., et al., Short hairpin RNA against PTEN enhances regenerative growth of 
corticospinal tract axons after spinal cord injury. J Neurosci, 2013. 33(39): p. 15350-61. 
55. Schmid, A.C., et al., Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS 
Lett, 2004. 566(1-3): p. 35-8. 
56. Mao, L., et al., Delayed administration of a PTEN inhibitor BPV improves functional 
recovery after experimental stroke. Neuroscience, 2013. 231: p. 272-81. 
 54 
57. Kim, S.R., et al., AAV transduction of dopamine neurons with constitutively active Rheb 
protects from neurodegeneration and mediates axon regrowth. Mol Ther, 2012. 20(2): p. 
275-86. 
58. Shahbazian, D., et al., eIF4B controls survival and proliferation and is regulated by 
proto-oncogenic signaling pathways. Cell Cycle, 2010. 9(20): p. 4106-9. 
59. Magnuson, B., B. Ekim, and D.C. Fingar, Regulation and function of ribosomal protein 
S6 kinase (S6K) within mTOR signalling networks. Biochem J, 2012. 441(1): p. 1-21. 
60. Efeyan, A. and D.M. Sabatini, mTOR and cancer: many loops in one pathway. Curr Opin 
Cell Biol, 2010. 22(2): p. 169-76. 
61. Thiem, S., et al., mTORC1 inhibition restricts inflammation-associated gastrointestinal 
tumorigenesis in mice. J Clin Invest, 2013. 123(2): p. 767-81. 
62. Zhu, R.L., et al., Intrinsic determinants of optic nerve regeneration. Chin Med J (Engl), 
2013. 126(13): p. 2543-7. 
63. Ma, L., et al., HDAC5-mTORC1 Interaction in Differential Regulation of Ghrelin and 
Nucleobindin 2 (NUCB2)/Nesfatin-1. Mol Endocrinol, 2015. 29(11): p. 1571-80. 
64. Perez de Sevilla Muller, L., et al., Melanopsin ganglion cells are the most resistant 
retinal ganglion cell type to axonal injury in the rat retina. PLoS One, 2014. 9(3): p. 
e93274. 
65. Schroeder, M.M., et al., The Roles of Rods, Cones, and Melanopsin in Photoresponses of 
M4 Intrinsically Photosensitive Retinal Ganglion Cells (ipRGCs) and Optokinetic Visual 
Behavior. Front Cell Neurosci, 2018. 12: p. 203. 
66. Witte, H., D. Neukirchen, and F. Bradke, Microtubule stabilization specifies initial 
neuronal polarization. J Cell Biol, 2008. 180(3): p. 619-32. 
67. Erturk, A., et al., Disorganized microtubules underlie the formation of retraction bulbs 
and the failure of axonal regeneration. J Neurosci, 2007. 27(34): p. 9169-80. 
68. Xiao, H., et al., Insights into the mechanism of microtubule stabilization by Taxol. Proc 
Natl Acad Sci U S A, 2006. 103(27): p. 10166-10173. 
69. Giannakakou, P., et al., A common pharmacophore for epothilone and taxanes: 
molecular basis for drug resistance conferred by tubulin mutations in human cancer 
cells. Proc Natl Acad Sci U S A, 2000. 97(6): p. 2904-9. 
70. Blanquie, O. and F. Bradke, Cytoskeleton dynamics in axon regeneration. Curr Opin 
Neurobiol, 2018. 51: p. 60-69. 
71. Hellal, F., et al., Microtubule stabilization reduces scarring and causes axon 
regeneration after spinal cord injury. Science, 2011. 331(6019): p. 928-31. 
72. Leo, L., et al., Vertebrate Fidgetin Restrains Axonal Growth by Severing Labile Domains 
of Microtubules. Cell Rep, 2015. 12(11): p. 1723-30. 
73. Wu, Q.F., et al., Fibroblast growth factor 13 is a microtubule-stabilizing protein 
regulating neuronal polarization and migration. Cell, 2012. 149(7): p. 1549-64. 
74. Martin-Montalvo, A., et al., Metformin improves healthspan and lifespan in mice. Nat 
Commun, 2013. 4: p. 2192. 
75. Diego, U.o.C.-S. Why are neuron axons long and spindly? Study shows they're 




76. Tremblay, R.G., et al., Differentiation of mouse Neuro 2A cells into dopamine neurons. J 
Neurosci Methods, 2010. 186(1): p. 60-7. 
77. Fan, S.F., et al., F11 neuroblastoma x DRG neuron hybrid cells express inhibitory mu- 
and delta-opioid receptors which increase voltage-dependent K+ currents upon 
activation. Brain Res, 1992. 590(1-2): p. 329-33. 
78. Sasaki, T., R. Fassler, and E. Hohenester, Laminin: the crux of basement membrane 
assembly. J Cell Biol, 2004. 164(7): p. 959-63. 
79. Kiani, C., et al., Structure and function of aggrecan. Cell Res, 2002. 12(1): p. 19-32. 
80. Huang, H., et al., AKT-dependent and -independent pathways mediate PTEN deletion-
induced CNS axon regeneration. Cell Death Dis, 2019. 10(3): p. 203. 
81. Leibinger, M., et al., GSK3-CRMP2 signaling mediates axonal regeneration induced by 
Pten knockout. Commun Biol, 2019. 2: p. 318. 
 
